Johnson & Johnson (NYSE:JNJ) target price raised to $125.00, reported today by Barclays PLC
- Updated: November 29, 2016
Johnson & Johnson (NYSE:JNJ) had its price target upped to $125.00 by Barclays PLC in an issued report issued 11/29/2016. The updated stock price target implies a possible upside of 0.11% from the company's most recent close.
On Friday February 05, 2016, Credit Suisse released a statement on Johnson & Johnson (NYSE:JNJ) bumped down the target price from $108.00 to $106.00 that suggested an upside of 0.05%.
Boasting a price of $112.52, Johnson & Johnson (NYSE:JNJ) traded -0.52% lower on the day. With the last close down -4.94% from the 200-day moving average, compared to the S&P 500 which has decreased -0.03% over the same time. The company has recorded a 50-day moving average of $115.97 and a 200-day moving average of $118.40. 2,794,061 shares of the stock were exchanged, down from an average trading volume of 6,833,040
See Chart Below
Johnson & Johnson has a 52 week low of $94.28 and a 52 week high of $126.07 with a P/E ratio of 19.76 The company’s market cap is currently $0.
In addition to Barclays PLC reporting its target price, a total of 18 firms have reported on the stock. The consensus target price is $117.44 with zero equity analysts rating the company a strong buy, zero equity analysts rating the company a buy, zero equity analysts rating the company a hold, zero equity analysts rating the company a underperform, and lastly zero equity analysts rating the company a sell.
Brief Synopsis About Johnson & Johnson (NYSE:JNJ)
Johnson & Johnson is a holding company, which is engaged in the research and development, manufacture and sale of a range of products in the healthcare field. The Company's segments include Consumer, Pharmaceutical and Medical Devices. The Consumer segment includes a range of products used in the baby care, oral care, skin care, over-the-counter pharmaceutical, women's health and wound care markets. The Pharmaceutical segment is focused on over five therapeutic areas, including immunology, infectious diseases, neuroscience, oncology, and cardiovascular and metabolic diseases. The Medical Devices segment includes a range of products used in the orthopedic, surgery, cardiovascular, diabetes care and vision care fields. Its research facilities are located in the United States, Belgium, Brazil, Canada, China, France, Germany, India, Israel, Japan, the Netherlands, Singapore, Switzerland and the United Kingdom.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with MarketBeat.com's FREE daily email newsletter.